New adjuvants: EU regulatory developments
- 1 October 2007
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Vaccines
- Vol. 6 (5) , 849-861
Abstract
This paper discusses EU regulatory texts that are relevant for the introduction of new adjuvants in human vaccines and discusses the EU requirements at the developmental level, during the manufacturing process and at the final product stage. The emphasis is on regulatory expectations regarding safety at preclinical and clinical stages. The article highlights regulatory concerns and existing bottlenecks that have led to a slow approval process for new adjuvants.Keywords
This publication has 82 references indexed in Scilit:
- Humoral and cell-mediated immune responses of humans to inactivated influenza vaccine with or without QS21 adjuvantVaccine, 2007
- Safety and Reactogenicity of an MSP-1 Malaria Vaccine Candidate: A Randomized Phase Ib Dose-Escalation Trial in Kenyan ChildrenPLoS Clinical Trials, 2006
- Oligodeoxynucleotide CpG 7909 Delivered as Intravenous Infusion Demonstrates Immunologic Modulation in Patients With Previously Treated Non-Hodgkin LymphomaJournal of Immunotherapy, 2006
- Phase I Evaluation of Intranasal Trivalent Inactivated Influenza Vaccine with Nontoxigenic Escherichia coli Enterotoxin and Novel Biovector as Mucosal Adjuvants, Using Adult VolunteersJournal of Virology, 2006
- A Phase I/II Trial of a WT1 (Wilms' Tumor Gene) Peptide Vaccine in Patients with Solid Malignancy: Safety Assessment Based on the Phase I DataJapanese Journal of Clinical Oncology, 2006
- Randomized Controlled Trial of an Adjuvanted Human Papillomavirus (HPV) Type 6 L2E7 Vaccine: Infection of External Anogenital Warts with Multiple HPV Types and Failure of Therapeutic VaccinationThe Journal of Infectious Diseases, 2005
- Safety and Immunogenicity of Glycoprotein D--Adjuvant Genital Herpes VaccineClinical Infectious Diseases, 2005
- Potent enhancement of cellular and humoral immune responses against recombinant hepatitis B antigens using AS02A adjuvant in healthy adultsVaccine, 2005
- Comparison of three different influenza vaccines in institutionalised elderlyVaccine, 2001
- QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immmunization in humansVaccine, 2001